Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500 mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg
Phase 1CompletedDevelopment Stage
Healthy Subjects in Fasted and Fed State
Healthy Subjects in Fasted and Fed State
Sep 26, 2017 → May 22, 2018
About Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500 mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg
Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500 mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 5/500mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg + Dapagliflozin/metformin XR 10/1000mg is a phase 1 stage product being developed by AstraZeneca for Healthy Subjects in Fasted and Fed State. The current trial status is completed. This product is registered under clinical trial identifier NCT03216278. Target conditions include Healthy Subjects in Fasted and Fed State.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216278 | Phase 1 | Completed |
Competing Products
20 competing products in Healthy Subjects in Fasted and Fed State
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |